Open label, randomized controlled trial of the selective PPAR-alpha modulator; Pemafibrate to the effect of urinary protein suppression in CKD patients with dyslipidemia - Open label, randomized controlled trial of the selective PPAR-alpha modulator; Pemafibrate to the effect of urinary protein suppression in CKD patients with dyslipidemia

kyushu university0 个研究点目标入组 140 人开始时间: 2020年11月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Using pemafibrate or some fibrates within 1 month before agreement. 2.Pregnant woman or woman being pregnancy during trial and lactating woman. 3.Allergy reaction to pemafibrate 4.Severe hepatic dysfunction or hepatic cirrhosis;Child-Pugh B or C or biliary obstruction. 5.Cholecystolithiasis 6.Serum Cr 2.5 mg/dL and over or CCr under 40 mL/min revised in November 2022 as follows; Patients on dialysis therapy or expected to require renal replacement therapy during the study period 7.Severe nephrosis necessary much amount of immunosuppressive agents or steroid. 8.After kidney transplantation 9.Cardiovascular events within 3 months before agreement. 10.Using cyclosporin or rifampicin 11.Familial hypercholesterinemia or familial hypoalphalipoproteinemia 12.History of myositis or myopathy or elevation of serum CPK; over 5 times ULN 13.Active malignancy 14.Severe infection

发起方